Polymyositis

Type: Keyphrase
Name: Polymyositis
First reported 18 hours ago - Updated 18 hours ago - 1 reports

CVS Caremark earns NCQA disease management accreditation certification for Accordant Health Services

Pharmacy CVS Caremark (NYSE:CVS) said on Monday that its Accordant Health Services division has been awarded the full NCQA Patient and Practitioner Oriented Disease Management (DM) accreditation in support of several diseases for programmes.The company ... [Published Individual.com - 18 hours ago]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Idera Pharmaceuticals and The Myositis Association Advance the Clinical Development of IMO-8400 for Myositis

CAMBRIDGE, Mass. & ALEXANDRIA, Va.--(BUSINESS WIRE)--Aug. 7, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis ... [Published Drugs.com - Aug 13 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 4 reports

Idera, TMA to advance clinical development of myositis treatment

Idera Pharmaceuticals and The Myositis Association (TMA) have collaborated to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. ... [Published PBR - News - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

New Inclusion Body Myositis Study Findings Reported from Tufts University (Aberrant cell cycle reentry in human and experimental inclusion body...

New Inclusion Body Myositis Study Findings Reported from Tufts University (Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis)By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results ... [Published 4 Traders - Aug 06 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Question regarding Pregnancy with PM

I'm having a hard time finding information about pregnancy and Polymyositis.I am 22 weeks, 6 days along; I have a regular OB, I see a Specialist and they work together with my Rheumy.I have ultrasounds every four -five weeks to measure the progress/development ... [Published HealthBoards - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis

The idiopathic inflammatory myopathies represent a group of autoimmune diseases that are characterized by lymphocyte infiltration in muscle and muscle weakness. Insulin-like 6 (Insl6) is a poorly characterized member of the relaxin/insulin-like family ... [Published 7thSpace - Aug 04 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Sjogren Syndrome

Medical Treatment Follow-up Web Links Sjögren's syndrome is a disorder of the moisture-producing glands, such as the tear glands (lacrimal glands) and the salivary glands. These glands become infiltrated with white blood cells (lymphocytes) that are part ... [Published eMedicine Health - Jul 30 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Questcor (QCOR) Misses on Q2 Earnings, Beats on Revenues

Questcor Pharmaceuticals Inc. ( QCOR ) reported second quarter 2014 earnings per share of $1.71, up from the year-ago earnings of $1.25 per share. Excluding share- based compensation expense, one-time items and non-cash expenses, earnings stood at $1.85 ... [Published Yahoo! Finance - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Questcor Reports Record Second Quarter Financial Results

/PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) today reported financial results for the second quarter ended June 30, 2014.Net sales for the second quarter ended June 30, 2014 were $278.8 million, up 51% from $184.6 million in GAAP net sales ... [Published Nasdaq - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Bristol-Myers Squibb and Ono Pharmaceutical Co., -2-

Immune-mediated Enterocolitis:-- In the pivotal Phase 3 study in Yervoy-treated patients, severe,life-threatening, or fatal (diarrhea of =7 stools above baseline, fever,ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitisoccurred in 34 (7%) ... [Published Scottrade - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Patients urged to 'partner' with caregivers

When Sarah Head first came to Emory University Midtown Hospital in 2010, she felt like her health was falling apart.She says, "I went from stumbling, to walking with a cane, to not walking at all."The Atlanta native, who’d moved to rural Tuskegee, Alabama, ... [Published Fox 5 Atlanta WAGA - Jul 21 2014]
First reported Mar 13 2014 - Updated Mar 13 2014 - 3 reports

Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell ... [Published EON Science - Mar 13 2014]

Quotes

...to help advance their novel TLR antagonist therapeutic approach in myositis," said Bob Goldberg, Executive Director of The Myositis Association. "We believe that the work Idera is doing will further the myositis medical field and our understanding of how to better treat patients suffering from this debilitating rare disease."
According to the news reporters, the research concluded: "The absence of rescue and evidence for reentry in separate models of myodegeneration and inflammation suggest that new DNA synthesis may be a reactive response to either or both stressors."
"In addition, our pilot effort focused on educating pulmonologists about Acthar in the treatment of respiratory manifestations of symptomatic sarcoidosis has generated a positive response over the last few months, consistent with our previous pilot detailing efforts in both nephrology and rheumatology. Prescribing activity by pulmonologists has exceeded our expectations since the pilot detailing effort began in February 2014, with approximately 40 to 45 new paid prescriptions shipped by pharmacies in the second quarter. As a result of these encouraging early results, we will be expanding the pulmonology sales force from 7 to 35 Acthar representatives and expect to complete this expansion by January 2015" concluded Mr. Cartt
The following quote was obtained by the news editors from the background information supplied by the inventors: "Chemokines are chemotactic proteins that have the potential to attract macrophages, T-cells, eosinophils, basophils, neutrophils and endothelial cells to sites of inflammation and tumor growth. Chemokines are typically low molecular mass (7-9 kD) proteins that can be divided into four subfamilies: CC (or .beta.-chemokines), CXC, C (or .gamma.-chemokines) and CX3C (or .delta.-chemokines). The chemokines are categorized through their primary amino acid structure. The CXC subfamily is characterized by two conserved Cys residues (C) near the N-terminus and separated by an amino acid (X). The CXC-chemokines include, for example, interleukin-8 (IL-8), neutrophil-activating protein-1 (NAP-1), neutrophil-activating protein-2 (NAP-2), GRO.alpha., GRO.beta., GRO.gamma., ENA-78, GCP-2, IP-10, MIG and PF4. The CXC subfamily of chemokines is further characterized by the presence or absence of a specific amino acid sequence, glutamic acid-leucine-arginine (or ELR for short) immediately before the first Cys residue of the CXC motif. Those chemokines with the ELR motif (ELRCXC) are important for the recruitment and activation of neutrophils to sites of inflammation. For example, GRO.alpha. and IL-8 are ELRCXC chemokines."

More Content

All (30) | News (22) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
CVS Caremark earns NCQA disease management accr... [Published Individual.com - 18 hours ago]
CVS Caremark’s Accordant Health Services Receiv... [Published Live Trading News - Aug 18 2014]
Agonists of neurotrophin receptors and their us... [Published PharmCast - Aug 14 2014]
Idera Pharmaceuticals and The Myositis Associat... [Published Drugs.com - Aug 13 2014]
Idera, TMA to advance clinical development of m... [Published PBR - News - Aug 08 2014]
Idera collaborates with TMA to advance new pote... [Published News-Medical.Net - Aug 07 2014]
Partnership Formed for Development of Myositis ... [Published Newswise - Aug 07 2014]
Idera Pharmaceuticals and The Myositis Associat... [Published Business Wire Health News - Aug 07 2014]
New Inclusion Body Myositis Study Findings Repo... [Published 4 Traders - Aug 06 2014]
Question regarding Pregnancy with PM [Published HealthBoards - Aug 06 2014]
The injury-induced myokine insulin-like 6 is pr... [Published 7thSpace - Aug 04 2014]
Sjogren Syndrome [Published eMedicine Health - Jul 30 2014]
Questcor (QCOR) Misses on Q2 Earnings, Beats on... [Published Yahoo! Finance - Jul 25 2014]
Questcor Reports Record Second Quarter Financia... [Published Nasdaq - Jul 24 2014]
Bristol-Myers Squibb and Ono Pharmaceutical Co.... [Published Scottrade - Jul 24 2014]
Patent Issued for Aminopyridine- and Aminopyrim... [Published 4 Traders - Jul 24 2014]
Patients urged to 'partner' with caregivers [Published Fox 5 Atlanta WAGA - Jul 21 2014]
Auto-Immune Self-Care Board? [Published HealthBoards - Apr 20 2014]
Targeted transforming growth factor-beta-bound ... [Published PharmCast - Apr 17 2014]
Mallinckrodt to acquire Questcor Pharmaceutical... [Published PharmaBiz - Apr 08 2014]
Idera Pharmaceuticals announces expansion of pi... [Published Pharmaceutical Business Review - Mar 14 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published EON Science - Mar 13 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Science: Science News - Mar 13 2014]
Idera Pharmaceuticals Announces Expansion of Pi... [Published Business Wire Health News - Mar 13 2014]
Anyone knowledgeable about scleroderma? [Published HealthBoards - Mar 05 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
Tetrameric cytokines with improved biological a... [Published PharmCast - Dec 17 2013]
Inhibitors of antigen presentation by MHC class... [Published PharmCast - Dec 15 2013]
Dual variable domain immunoglobulins and uses t... [Published PharmCast - Dec 06 2013]
Engineered antibody constant domain molecules [Published PharmCast - Nov 26 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Idera, TMA to advance clinical development of m... [Published PBR - News - Aug 08 2014]
Idera Pharmaceuticals and The Myositis Association (TMA) have collaborated to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. ...
Idera Pharmaceuticals and The Myositis Associat... [Published Business Wire Health News - Aug 07 2014]
CAMBRIDGE, Mass. & ALEXANDRIA, Va.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), ...
Question regarding Pregnancy with PM [Published HealthBoards - Aug 06 2014]
I'm having a hard time finding information about pregnancy and Polymyositis.I am 22 weeks, 6 days along; I have a regular OB, I see a Specialist and they work together with my Rheumy.I have ultrasounds every four -five weeks to measure the progress/development ...
Auto-Immune Self-Care Board? [Published HealthBoards - Apr 20 2014]
Hi board community,I am posting in the autoimmune forum, because I am waiting for my initial visit with a rheumatologist. Lab work was: ANA 1,280, positive for rheumatoid factor, low level of c-reactive protein. Symptoms: Hand and wrist arthritis, swelling ...
Idera Pharmaceuticals Announces Expansion of Pi... [Published EON Science - Mar 13 2014]
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.